While most mutations in the three monoclonal tumors were detected in all tumor cells, there were a few mutations identified that occurred at lower frequencies, including MED24 (4.8%) in TN3 and OTUD5 (3.2%) and PRDM5 (2%) in TN5, as well as SENP6, MARCH6, PODXL2, and ADCY8 (all at 1.8%) of cells in TN5, suggesting that these were later lineage events that emerged during tumor progression. Here, PRDM5 is linked to neoplasm.